Deep Longevity plans to launch Accrua, a telehealth platform using BloodAge testing to guide care, though clinical outcome data remains unproven.
On September 28, 2026, Regent Pacific Group announced that its subsidiary, Deep Longevity, planned to launch a new telehealth platform called Accrua. The announcement cited a 2026 paper in Aging and Disease by Goshen and colleagues to support the clinical model.
Deep Longevity anchors its new clinical approach to this observational study of approximately 2,600 adults tracked over an average of 9.2 years. The company notes that this research identified a significant population-level risk signal related to accelerated aging. Specifically, the study reported that each additional year of difference between biological and chronological age was associated with a 15% increase in mortality risk. While this reported association forms the theoretical foundation for the platform, the cited article does not establish that treatment decisions based on BloodAge actually improve health outcomes.
The cited research evaluating the mortality risk associated with this biological-age gap was conducted in human adults.
Deep Longevity generates its proprietary BloodAge report by applying an artificial intelligence model directly to routine blood-test data. This assessment estimates whether a person might be aging biologically faster than their chronological age. The AI model analyzes patterns across standard laboratory values to generate its final output. By comparing an individual patient against massive datasets, the system calculates a specific biological-age estimate.
Regent Pacific says clinicians will use the BloodAge report to personalize medical treatment plans. This approach aims to provide a comprehensive alternative to relying only on self-reported symptoms or a single isolated biomarker. The company states that the Accrua platform will repeat this measurement quarterly so users and clinicians can track changes over time. Integrating AI-driven insights into routine blood testing represents a growing trend in the commercial medical sector.
However, consistent biomarker monitoring requires highly careful clinical interpretation. A biological-age estimate should be understood strictly as a measurement or risk-related signal. It is not a definitive clinical diagnosis or a reliable forecast of an individual lifespan. Relying on an isolated metric without considering lifestyle, genetics, and detailed family history can lead to unnecessary anxiety.
Evaluating biological age testing methods requires clearly separating observational population data from validated clinical diagnostics. The 15% mortality increase per year of biological-age gap is purely an observational association. It identifies a correlation within a broad group of people over a specific period. It does not prove that actively trying to lower that score will directly extend a person's life.
Many consumers mistakenly view a higher biological age score as an immediate medical crisis. In reality, it functions more like a warning signal that requires much broader medical context. Observing a mathematical trend over nearly a decade is fundamentally different from proving that a specific medical intervention can alter that trend safely.
The stark distinction between observing a risk and proving a treatment works is central to evaluating this telehealth service. Longevity.Technology explicitly identifies a critical open question regarding this direct-to-consumer model. It remains entirely unclear whether selecting a treatment based on the BloodAge score leads to better patient outcomes. The available materials report no clinical-outcome data from existing Accrua users, nor do they demonstrate that BloodAge-guided treatment reduces mortality effectively.
Regent Pacific stated that Deep Longevity planned to launch Accrua in the United States in October 2026. Longevity.Technology reported the exact same planned launch date for the digital platform. The company noted that Accrua was intended to be available across all 50 states. However, initial marketing efforts will focus primarily on selected states rather than attempting a simultaneous national rollout.
Launching regionally allows the company to test its systems before expanding further. This launch marks Deep Longevity’s significant move into direct-to-consumer U.S. healthcare services. The company previously operated mostly through business-to-business relationships with independent clinics, hospitals, laboratories, and large insurers.
Regent Pacific says care will be delivered through external U.S. telehealth infrastructure partners, independent licensed physicians, and designated pharmacy partners. The digital platform will operate on HIPAA-compliant infrastructure to protect patient data securely. The company also stated that the platform would secure LegitScript certification ahead of the formal launch.
Deep Longevity confirmed that it will not own clinical infrastructure or directly carry any drug inventory for the Accrua platform. Instead, the telehealth service relies entirely on its established network of external care and fulfillment partners. Operating without owned clinical infrastructure allows the platform to scale rapidly across multiple state lines. This decentralized approach relies heavily on the quality and consistency of the independent medical providers in the network.
By strictly utilizing external partners, the company reduces its immediate overhead costs significantly. The company expects revenue to be largely subscription-based, reflecting a very common structure in modern telehealth. Neither the Regent Pacific announcement nor the Longevity.Technology report specifies a direct consumer price for the service.
Regent Pacific CEO Jamie Gibson called the intended launch a landmark moment for the business. He stated that the company believes anchoring treatment to biological age rather than symptoms alone is a new proposition. This statement strictly reflects an executive’s personal characterization of the service. It does not serve as independent scientific evidence that this specific approach is clinically novel or highly effective.
To illustrate potential market scale, the company invoked the revenue of adjacent digital-health businesses. Regent Pacific cited MEDVi revenue of more than US$400 million in 2025. The company also referenced an approximately US$1.8 billion revenue run-rate for MEDVi in 2026. Regent Pacific cautioned that there was no assurance Accrua would achieve comparable results, noting that future revenues remain uncertain.
Using artificial intelligence to interpret routine blood tests is a major shift in how the industry handles basic medical data. Historically, physicians reviewed standard lipid panels and metabolic markers to identify immediate diseases or severe deficiencies. The Accrua model attempts to repurpose these traditional markers to calculate a broader trajectory of systemic aging. This computational approach mathematically groups various subtle changes that might otherwise go unnoticed during a standard annual physical.
While this analytical capability is mathematically impressive, clinical utility is an entirely different standard. An AI algorithm can easily find complex patterns in large datasets, but those patterns do not automatically dictate the correct medical intervention. Research-minded adults must remain highly analytical when reviewing platforms that market AI as a primary diagnostic authority. A sophisticated algorithm is only a tool to assist human clinicians, not a definitive replacement for thorough medical judgment.
After completing a clinician consultation, Accrua users may be offered doctor-guided access to several prescription therapies. The company says these options include weight-loss medications such as GLP-1 therapies, various peptides, women’s health treatments, and men’s health treatments. Integrating these specific pharmaceutical categories reflects massive consumer interest in emerging longevity therapeutics. Peptides and GLP-1 medications represent powerful biological interventions that require precise clinical dosing and continuous monitoring.
The company claims independent clinicians will personalize treatment plans using the BloodAge report. However, the public announcement does not describe any detailed eligibility criteria for these prescription medications. It is not clear how clinicians will weigh the biological-age score against standard clinical information or pre-existing conditions. Prescribing powerful compounds based primarily on an aging algorithm remains an unproven approach in standard medical practice.
If a service discusses GLP-1 medicines or other active treatments, readers must distinguish between a score informing a discussion and a score proving a treatment is medically necessary. The available reporting supports the idea that the BloodAge score will inform the clinician’s initial discussion. It does not establish that the score is proven to select a better long-term treatment pathway. Readers should not assume a quarterly score will independently determine their medical care.
The report describes quarterly remeasurement as a distinct way to track health progress continuously. This high frequency of testing introduces significant clinical challenges for both patients and their attending physicians. Longevity.Technology raises the critically important question of how well the score tracks health in a specific individual rather than in a general population. Repeated physiological measurements can fluctuate due to short-term dietary changes, mild dehydration, or minor seasonal infections.
These natural biological fluctuations raise difficult questions about how clinicians and users should interpret changing quarterly numbers. A temporary change in a standard blood panel might alter the AI-generated score without reflecting a true shift in long-term aging. Navigating these cellular health and metabolic changes requires careful, highly trained medical oversight. The public materials do not explain exactly what a changed quarterly score would mean for an ongoing treatment plan.
Patients may feel pressured to adjust their medications every three months based solely on these shifting algorithmic numbers. A truly effective longevity protocol requires consistent adherence rather than constant reactionary adjustments.
To accurately assess this new platform, several critical study and operational limitations must be recognized:
Validating whether anchoring complex prescription decisions to an AI-driven biological-age estimate actually improves patient health requires waiting for large, properly controlled clinical trials.
Assessing whether routine blood panels can accurately guide complex longevity prescriptions requires strictly separating observational risk data from proven treatment outcomes. To resolve the ongoing confusion over conflicting longevity studies, AgeAmaze provides research-minded adults with careful analyses of emerging platforms so they can evaluate new clinical tools accurately.
Stay current with research on aging biology, biomarkers, nutrition, therapeutics, peptides and longevity technology. AgeAmaze reports what the evidence shows, where uncertainty remains and which claims still need stronger data.
Follow AgeAmaze for careful reporting on what longevity science can show today and what still needs stronger evidence.
read the Blog
